Search Results - "CEUPPENS, Peter"

Differentiating multichannel block on the guinea pig ECG: Use of Tpeak-Tend and J-Tpeak by Skinner, Matt, Hale, Ed, Ceuppens, Peter, Pollard, Chris

“…The anaesthetised guinea pig is a well characterised assay for early assessment of drug effects on ventricular repolarisation and risk of Torsade de Pointes…”
Get full text

In search of preclinical robustness by Peers, Ian S., Ceuppens, Peter R., Harbron, Chris

“…Systematic engagement of statisticians in preclinical research could help address the weaknesses that are undermining the likelihood of subsequent success in…”
Get full text

Can you trust your animal study data? by Peers, Ian S., South, Marie C., Ceuppens, Peter R., Bright, Jonathan D., Pilling, Elizabeth

Get full text

Social-housing and use of double-decker cages in rat telemetry studies by Skinner, Matt, Ceuppens, Peter, White, Peter, Prior, Helen

“…Rat telemetry is widely used for biomedical research purposes and is used routinely in early pre-clinical drug development to screen for the potential…”
Get full text

177 Lu-Lilotomab Satetraxetan Has the Potential to Counteract Resistance to Rituximab in Non-Hodgkin Lymphoma by Malenge, Marion M, Patzke, Sebastian, Ree, Anne H, Stokke, Trond, Ceuppens, Peter, Middleton, Brian, Dahle, Jostein, Repetto-Llamazares, Ada H V

“…Patients with non-Hodgkin lymphoma (NHL) who are treated with rituximab may develop resistant disease, often associated with changes in expression of CD20. The…”
Get full text

177Lu-Lilotomab Satetraxetan Has the Potential to Counteract Resistance to Rituximab in Non-Hodgkin Lymphoma by Malenge, Marion M, Patzke, Sebastian, Ree, Anne H, Stokke, Trond, Ceuppens, Peter, Middleton, Brian, Dahle, Jostein, Repetto-Llamazares, Ada HV

“…Patients with non-Hodgkin lymphoma (NHL) who are treated with rituximab may develop resistant disease, often associated with changes in expression of CD20. The…”
Get full text

In search of preclinical robustness: systematic engagement of statisticians in preclinical research could help address the weaknesses that are undermining the likelihood of subsequent success in drug discovery and development by Peers, Ian S, Ceuppens, Peter R, Harbron, Chris

Get full text

High content screening of patient-derived cell lines highlights the potential of non-standard chemotherapeutic agents for the treatment of recurrent glioblastoma by Taylor, Jessica, Yu, Kenny, Pathmanaban, Omar, Beyit, Deniz, Dutko-Gwozdz, Joanna, Benson, Rod, Griffiths, Gareth, McBain, Catherine, Peers, Ian, Ceuppens, Peter, Kamaly-asl, Ian, Bigger, Brian

“…Glioblastoma Multiforme (GBM) is the most common primary brain tumour in adults, yet survival outcomes remain poor. First line treatment is well established…”
Get full text

EXTH-57. HIGH CONTENT SCREENING OF PATIENT-DERIVED CELL LINES HIGHLIGHTS THE POTENTIAL OF NON-STANDARD CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF RECURRENT GLIOBLASTOMA by Taylor, Jessica, Yu, Kenny, Pathmanaban, Omar, Beyit, Deniz, Dutko-Gwozdz, Joanna, Benson, Rod, Griffiths, Gareth, Telfer, Brian, Williams, Kaye, Peers, Ian, Ceuppens, Peter, McBain, Catherine, Kamaly-Asl, Ian, Bigger, Brian

Get full text

Determination of the safety and efficacy of therapeutic neutralization of tumor necrosis factor-α (TNF-α) using AZD9773, an anti-TNF-α immune Fab, in murine CLP sepsis by Newham, Peter, Ross, Daniel, Ceuppens, Peter, Das, Shampa, Yates, James W. T., Betts, Catherine, Reens, Jaimini, Randall, Kevin J., Knight, Richard, McKay, Jennifer S.

“…Objective and design TNF-α neutralization is associated with increased mortality in mouse cecal ligation puncture (CLP) models. AZD9773 is an ovine polyclonal…”
Get full text

Biostatistical methodology in carcinogenicity studies by FAIRWEATHER, W. R, BHATTACHARYYA, A, SOPER, K. A, STALLARD, N, VENTRE, J, WRIGHT, J, CEUPPENS, P. P, HEIMANN, G, HOTHORN, L. A, KODELL, R. L, LIN, K. K, MAGER, H, MIDDLETON, B. J, SLOB, W

Get full text

Determination of the safety and efficacy of therapeutic neutralization of tumor necrosis factor-[alpha] (TNF-[alpha]) using AZD9773, an anti-TNF-[alpha] immune Fab, in murine CLP sepsis by Newham, Peter, Ross, Daniel, Ceuppens, Peter, Das, Shampa, Yates, James W; T, Betts, Catherine, Reens, Jaimini, Randall, Kevin J, Knight, Richard, Mckay, Jennifer S

“…TNF-[alpha] neutralization is associated with increased mortality in mouse cecal ligation puncture (CLP) models. AZD9773 is an ovine polyclonal human…”
Get full text

Characterization of the complex formed between a potent neutralizing ovine-derived polyclonal anti-TNFα Fab fragment and human TNFα by Abbott, W Mark, Snow, Melanie, Eckersley, Sonia, Renshaw, Jonathan, Davies, Gareth, Norman, Richard A, Ceuppens, Peter, Slootstra, Jerry, Benschop, Joris J, Hamuro, Yoshitomo, Lee, Jessica E, Newham, Peter

“…TNFα (tumour necrosis factor α) is an early mediator in the systemic inflammatory response to infection and is therefore a therapeutic target in sepsis…”
Get full text

ARMSallele-specific amplification-based detection of mutant p53 DNA and mRNA in tumors of the breast by HODGSON, Darren R, CLAYTON, Simon J, WHITCOMBE, David, GIBSON, Neil J, GIRDLER, Fiona, BROTHERICK, Ian, SHENTON, Brian, BROWELL, David, STUART, Mary, FOX, Jayne C, CEUPPENS, Peter, FOY, Carole A

Get full text

ARMS allele-specific amplification-based detection of mutant p53 DNA and mRNA in tumors of the breast by Hodgson, D R, Clayton, S J, Girdler, F, Brotherick, I, Shenton, B, Browell, D, Stuart, M, Fox, J C, Ceuppens, P, Foy, C A, Whitcombe, D, Gibson, N J

Get full text

Carcinogenicity Testing of Pharmaceuticals in the European Union: A Workshop Report by Spindler, Per, van der Laan, Jan-Willem, Ceuppens, Peter, Harling, Robert, Ettlin, Robert, Lima, Beatriz Silva

Get full text

Carcinogenicity testing of pharmaceuticals in the European Union : A workshop report: Special Issue on Regulatory Affairs by SPINDLER, Per, VAN DER LAAN, Jan-Willem, CEUPPENS, Peter, HARLING, Robert, ETTLIN, Robert, LIMA, Beatriz Silva

Get full text